Glaxo Initiates Phase III Study - Analyst Blog

By
A A A

Genmab ( GNMSF ) recently announced that its partner GlaxoSmithKline ( GSK ) has initiated a phase III study (n ~ 136) on a subcutaneous formulation of their marketed drug Arzerra (ofatumumab) for an additional indication. The double blind phase III study will evaluate the safety and efficacy of Arzerra in patients suffering from pemphigus vulgaris, a rare skin related autoimmune disorder.

We note that Arzerra was approved in Oct 2009 for the treatment of patients with chronic lymphocytic leukemia (CLL), a type of blood cancer, refractory to Sanofi 's ( SNY ) Campath (alemtuzumab) and Fludara (fludarabine). In the first quarter of 2013, Glaxo reported Arzerra revenues of £21 million, up 67% from the year-ago quarter.

Glaxo and Genmab are looking to expand the label of Arzerra. In May 2013, Glaxo and Genmab announced encouraging top-line data from a phase III study (n = 447) which compared the efficacy of Arzerra as an adjunct to another oncology drug at Glaxo, Leukeran (chlorambucil) in treatment-naive CLL patients versus Leukeran alone.

The study met its primary endpoint of progression free survival (PFS/the time a patient lived without worsening of their disease). Data from the study was assessed by an independent review committee. In the Arzerra + Leukeran arm of the study, median PFS of 22.4 months was observed as compared to 13.1 months in the Leukeran arm.

Glaxo carries a Zacks Rank #3 (Hold). We are pleased with Glaxo's label expansion efforts. Moreover, Glaxo boasts of a robust pipeline. A number of pipeline-related news is expected in the coming quarters. Given the declining sales from generic competition, we believe Glaxo's pipeline must deliver. Companies that currently look attractive include Novo Nordisk ( NVO ) carrying a Zacks Rank #2 (Buy).



GENMAB A/S (GNMSF): Get Free Report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: GNMSF , GSK , NVO , SNY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

80%
50%
100%

Most Active by Volume

270,887,127
    $93.89 unch
225,243,115
  • $40.93 ▼ 2.74%
135,900,109
  • $47.52 ▲ 1.80%
89,467,924
  • $5.35 ▼ 1.11%
85,105,358
  • $16.95 ▼ 0.53%
80,748,539
  • $39.80 ▼ 4.21%
68,491,586
  • $3.57 ▼ 1.79%
62,097,356
  • $100.96 ▼ 0.82%
As of 9/19/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com